TCGA-96-7545-01A-21R-2045-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.390
- ANDROGEN_RESPONSE+0.380
- IL2_STAT5_SIGNALING+0.360
- ESTROGEN_RESPONSE_EARLY+0.350
- PROTEIN_SECRETION+0.350
- TGF_BETA_SIGNALING+0.340
- APICAL_SURFACE+0.320
- HEDGEHOG_SIGNALING+0.320
- INFLAMMATORY_RESPONSE+0.310
- KRAS_SIGNALING_UP+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.370
- DNA_REPAIR-0.300
- MYC_TARGETS_V2-0.220
- INTERFERON_GAMMA_RESPONSE-0.150
- E2F_TARGETS-0.140
- G2M_CHECKPOINT-0.080
- PANCREAS_BETA_CELLS-0.030
- GLYCOLYSIS-0.010
- SPERMATOGENESIS-0.010
- NOTCH_SIGNALING+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-7338-01A-11R-2045-07 | — | cohortSQ2 | 0.819 |
| 2 | MNG1059 | — | — | 0.814 |
| 3 | TCGA-CN-4729-01A-01R-1436-07 | — | — | 0.795 |
| 4 | MBCProject_4232_T1_RNA | — | A | 0.792 |
| 5 | D65697C7-2DA7-43BA-ABE2-50CB08B0D126 | — | — | 0.791 |
| 6 | MNG967 | — | — | 0.791 |
| 7 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.790 |
| 8 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.783 |
| 9 | ULC1700T_S19 | — | cohortMD2 | 0.776 |
| 10 | MNG1023 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |